TearClear: TearClear Files Investigational New Drug (IND) Application to Begin its Clinical Trial for TC-002 Latanoprost Ophthalmic Solution, 0.005%

(marketscreener.com) BOSTON, Sept. 08, 2021 -- TearClear, a late clinical stage ophthalmic pharmaceutical company, has filed an Investigational New Drug application to conduct a registrational study for its lead glaucoma candidate, TC-002 latanoprost ophthalmic solution, 0.005%. Approximately 30%-40% of patients who rely on preserved,...https://www.marketscreener.com/news/latest/TearClear-Files-Investigational-New-Drug-IND-Application-to-Begin-its-Clinical-Trial-for-TC-002-La--36375493/?utm_medium=RSS&utm_content=20210908